Home › Astra Signals A Late Run On BTK Inhibition
 

Keywords :   


Astra Signals A Late Run On BTK Inhibition

2015-12-14 19:08:14| Biotech - Topix.net

This morning's confirmation that AstraZeneca had made an approach to Acerta Pharma casts the spotlight on what is a private biotech that has quietly positioned itself as the most advanced developer of a BTK inhibitor after AbbVie 's blockbuster Imbruvica . Have you spotted the link? AbbVie had acquired Imbruvica through a $21bn takeover of Pharmacyclics , and Acerta was founded by Ahmed Hamdy- none other than Pharmacyclics ' ex-chief medical officer.

Tags: run late signals inhibition

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
08.11Nissan to lay off thousands of workers as sales drop
08.11Hurricane Rafael Graphics
08.11Hurricane Rafael Wind Speed Probabilities Number 18
08.11Hurricane Rafael Forecast Discussion Number 18
08.11Hurricane Rafael Forecast Advisory Number 18
08.11Hurricane Rafael Public Advisory Number 18
08.11Summary for Hurricane Rafael (AT3/AL182024)
08.11Up close with the 300 tonne driverless trucks
More »